ZOLL Medical revenues for third-quarter fiscal 2010 up 17% to $111.3 million

Jul 29 2010

ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced that revenues for the third quarter of fiscal 2010 increased 17% to $111.3 million, compared to revenues in the third quarter of last year of $95.1 million. The third quarter 2010 results included approximately $5.0 million of revenue from the Temperature Management business, compared to $1.9 million of revenue in the third quarter of last year. The Temperature Management business includes the assets which were acquired from Alsius Corporation in May 2009. Net income was $5.7 million for the quarter, an increase of 285%, compared to $1.5 million in the prior year. Diluted earnings per share were $0.26, compared to $0.07 in the prior year. Backlog at the end of the third quarter was approximately $14 million, as compared to approximately $10 million at the end of Q3 2009.

“Overall, Q3 was continued progress. Our bottom line is growing strongly as the core business rebounds and profitability builds in the newer product lines. We look forward to finishing the year on plan, and we look forward to 2011 where we expect to make additional strides in growing our profitability.”

Third quarter sales to the North American market were $81.9 million, an increase of 13%, compared to $72.8 million for the prior-year period. Due to less Military business, sales to the North American hospital market decreased 8%, to $24.5 million (including $2.6 million related to the Temperature Management business), compared to $26.6 million for the same period last year. Excluding Military and Temperature Management revenues, North American hospital sales increased 9%, compared to the same period last year. US Military sales were $3.4 million in the third quarter of fiscal 2010, compared to $8.8 million for the same period in the prior year.

Sales to the North American pre-hospital market increased 26% to $51.1 million, compared to $40.5 million in the prior year. International sales, including $2.4 million related to the Temperature Management business, increased 31% to $29.4 million, compared to $22.4 million last year. LifeVest® revenues increased 51% to $18.0 million. Total AutoPulse® sales decreased 6% to $3.8 million, compared to $4.1 million in the third quarter of last year.

Gross margin for the third quarter was 54%, compared to 51% in the third quarter of fiscal 2009. The increase primarily reflected improved pricing in the North American core defibrillator business.

Richard A. Packer, Chief Executive Officer of ZOLL, commented, "We were pleased with our results again this quarter as we achieved high growth with the LifeVest and Temperature Management products. We continue to make modest progress with the core business, where once again International results were strong and the US market continues to be a bit of a challenge."

Mr. Packer stated, "The prospects for both our LifeVest and Temperature Management businesses are very bright. As planned, we resumed adding to the LifeVest sales force, which will help keep us on track to achieve our growth rate of 60% for the year. In Germany, we continue to work through the transition of both these businesses from the previous distributor partners to ZOLL's own direct efforts. This transition has slowed our sales growth in the short term, but we can already see positive momentum building in this key market."

With respect to the LifeVest product, Mr. Packer noted, "The recent publication of aggregate experience with the LifeVest, from over 3,500 patients, by Dr. Chung of the Cleveland Clinic, in the Journal of American College of Cardiology adds significantly to the growing body of clinical evidence supporting regular use of the LifeVest. The noteworthy results included patient compliance greater than 90%, first treatment shock conversion efficacy at 99%, and survival during LifeVest use at over 99%. We expect this data, and the associated editorial, to aid our efforts to gain widespread use of the LifeVest by the cardiology community."

Mr. Packer further commented, "The core North American hospital again showed modest growth as that market rebounds slowly. We received very little Military business during the quarter, as our customers wait on FDA clearance of the new military product, which we now believe is imminent. A large shipment to Canada, which standardized the EMS system in Newfoundland to ZOLL, helped us achieve growth in the North American EMS market in spite of continued spending constraints in the US. We remain cautious about the outlook for the EMS market in the US."

Mr. Packer observed, "Adding further to the strength of our International prospects, we were pleased to announce, via a separate release, that we have received approval from the Japanese authorities for the AED Plus^® and AED Pro^®. Getting our unique biphasic waveform approved has taken many years, virtually locking our defibrillators out of the large Japanese market. We look forward to announcing a distribution agreement with a significant partner in the near future and beginning shipments before the end of the year. The Japanese market represents another significant growth opportunity for ZOLL."

Mr. Packer also noted, "During the quarter, one of the challenges facing our International business was foreign exchange. We did experience negative foreign exchange movements within Q3, but we were able to offset those adverse effects with a discrete tax benefit that significantly reduced this quarter's tax rate."

Mr. Packer concluded, "Overall, Q3 was continued progress. Our bottom line is growing strongly as the core business rebounds and profitability builds in the newer product lines. We look forward to finishing the year on plan, and we look forward to 2011 where we expect to make additional strides in growing our profitability."

SOURCE ZOLL Medical Corporation